Dianthus Therapeutics (NASDAQ:DNTH) Stock: Insider Ryan Savitz Sells 17,724 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 17,724 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $90.56, for a total value of $1,605,085.44. Following the transaction, the executive vice president directly owned 29,276 shares of the company’s stock, valued at $2,651,234.56. The trade was a 37.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total value of $274,051.32.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.54, for a total value of $9,118,555.02.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.14, for a total value of $230,848.54.

Dianthus Therapeutics Stock Performance

Shares of DNTH traded up $3.18 during trading hours on Thursday, hitting $92.48. 921,016 shares of the stock were exchanged, compared to its average volume of 931,449. The stock’s 50-day moving average price is $89.05 and its two-hundred day moving average price is $86.15. Dianthus Therapeutics, Inc. has a 12-month low of $34.29 and a 12-month high of $117.88. The company has a market cap of $5.21 billion, a price-to-earnings ratio of -23.18 and a beta of 1.47.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The company had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current year.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of recent research reports. Citigroup initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 target price for the company. Roth Capital assumed coverage on shares of Dianthus Therapeutics in a research report on Tuesday, October 27th. They set a “buy” rating and a $113.00 price target on the stock. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $158.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $128.77.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. BlackRock Inc. purchased a new stake in Dianthus Therapeutics in the 2nd quarter valued at $401,990,000. Wellington Management Group LLP increased its holdings in shares of Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after buying an additional 634,099 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock worth $64,474,000 after buying an additional 451,597 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at approximately $40,713,000. Finally, Pictet Asset Management Holding SA raised its position in shares of Dianthus Therapeutics by 86.9% during the 3rd quarter. Pictet Asset Management Holding SA now owns 462,290 shares of the company’s stock valued at $40,705,000 after buying an additional 214,995 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.